LEXARIA BIOSCIENCE CORP. Accounts Payable and Other Accrued Liabilities
LEXARIA BIOSCIENCE CORP. (LEXX) had Accounts Payable and Other Accrued Liabilities of $350.38 thousand as of 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:AccountsPayableAndOtherAccruedLiabilities · last filed 2026-07-13
- 2026-05-31: Accounts Payable and Other Accrued Liabilities $350.38K.
- 2026-02-28: Accounts Payable and Other Accrued Liabilities $182.61K.
- 2025-11-30: Accounts Payable and Other Accrued Liabilities $1.43M.
- 2025-08-31: Accounts Payable and Other Accrued Liabilities $1.46M.
| Period end | Accounts Payable and Other Accrued Liabilities |
|---|---|
| 2026-05-31 | $350.38K 10-Q · filed 2026-07-13 |
| 2026-02-28 | $182.61K 10-Q · filed 2026-04-13 |
| 2025-11-30 | $1.43M 10-Q · filed 2026-01-13 |
| 2025-08-31 | $1.46M 10-Q · filed 2026-07-13 |
| 2025-05-31 | $1.46M 10-Q · filed 2025-07-14 |
| 2025-02-28 | $1.79M 10-Q · filed 2025-04-14 |
| 2024-11-30 | $268.99K 10-Q · filed 2025-01-10 |
| 2024-08-31 | $1.07M 10-K · filed 2025-11-28 |
| 2024-05-31 | $128.79K 10-Q · filed 2024-07-12 |
| 2024-02-29 | $55.32K 10-Q · filed 2024-04-09 |
| 2023-11-30 | $98.97K 10-Q · filed 2024-01-12 |
| 2023-08-31 | $239.94K 10-K · filed 2024-11-26 |
| 2023-05-31 | $1.02M 10-Q · filed 2023-07-14 |
| 2023-02-28 | $189.78K 10-Q · filed 2023-04-14 |
| 2022-11-30 | $241.89K 10-Q/A · filed 2023-01-18 |
| 2022-08-31 | $151.45K 10-K · filed 2023-11-20 |
| 2021-08-31 | $105.95K 10-K · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |